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Abstract
Three different Maltese scientists have contributed to 
research on the link between cannabis and psychosis. The object 
of this article is to review and chronicle the work that has been 
done by these three colleagues in this field. Work has helped 
to establish whether cannabis causes psychosis, whether the 
continued use of cannabis by patients with schizophrenia affects 
the course of the disease and its treatment, and whether or not 
it is possible to change the habit of cannabis use in patients who 
have a psychotic disorder.
Introduction
The relationship between cannabis and psychosis has been 
the focus of much study in recent years. Fortuitously, much work 
in this area has been carried out by Maltese researchers, mostly 
working in the UK, but on occasion in Malta. This contribution 
outlines the Maltese contribution to medical knowledge in this 
field.
Does cannabis cause psychosis 
[schizophrenia]?
There has been much debate recently as to whether cannabis 
use increases the risk of developing chronic psychotic disorders 
such as schizophrenia. The first study to provide compelling 
evidence that cannabis use may cause schizophrenia was that 
of Andreasson & Allebeck,1 who carried out a 15 year follow 
up of 50 465 Swedish Conscripts who had self reported on 
their cannabis use at age 18. They found that those who tried 
cannabis by age 18 years were 2.4 times more likely to develop 
schizophrenia than those who had not. The risk of developing 
schizophrenia was related in a dose–response way to the number 
of times cannabis had been used. Compared with those who had 
not used cannabis, the risk of developing schizophrenia was 1.3 
times higher for individuals who had used cannabis 1 to 10 times, 
3 times higher for individuals who had used cannabis between 
1 and 50 times, and with a 6-fold increase in risk for those 
who had used cannabis more than 50 times. These risks were 
substantially reduced, but persisted nevertheless, after statistical 
adjustment for variables that could confound, or explain, this 
association, including having a psychiatric illness at age 18 years 
and having divorced parents. In the adjusted analusis, those 
who used cannabis 1 to 10 times were 1.5 times more likely, 
and those who used cannabis 10 times or more 2.3 times more 
likely to develop schizophrenia, compared with individuals who 
never used cannabis. Although Andreasson and others argued 
that these findings supported a causal relationship between 
cannabis and schizophrenia, a number of limitations were raised 
regarding this study. As a means to address these limitations, a 
follow-up study of this same cohort was conducted by Stanley 
Zammit,2 a Maltese Doctor working in Cardiff, and others who 
reported risk of schizophrenia over a 27-year follow-up period 
that covered most of the risk period for the onset of psychotic 
disorders. This study improved on the original study in a number 
of ways. First, the psychiatric register provided more complete 
coverage of all individuals diagnosed with schizophrenia. 
Second, statistical control was improved and included a wider 
range of potentially important confounding variables, including 
other drug use, IQ, social integration and other established risk 
factors for schizophrenia. Third, to examine the possible role of 
a prodrome of schizophrenia leading to cannabis use at age 18 
(the ‘self-medication hypothesis’), the authors also examined 
cases that occurred more than 5 years after conscription, by 
which time any prodrome of schizophrenia would have been 
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Grech and others also have recently studied cannabis use 
and outcome of recent onset psychosis.6-8 They wished to test 
the hypothesis that recent onset psychotic patients who use 
cannabis will have psychotic symptoms that are more severe 
and more persistent than those who do not use cannabis. They 
carried out a 4-year follow-up study of a cohort of 119 patients 
with recent onset of psychosis. The patients were divided into 
four groups according to duration of cannabis use, taking index 
admission and follow-up as reference points. Those subjects 
who persisted in the use of cannabis had more positive (but 
not negative) symptoms and a more continuous illness at 
follow-up. The main limitations of the study were: the relatively 
small sample size, and that the excess of male subjects and the 
presence of cannabis induced psychosis could have a confusing 
impact on the interpretation of the results. They concluded that 
it is possible that psychotic patients who use cannabis are at a 
greater risk of a more continuous illness with more positive 
symptoms than those who do not. 
Zammit and colleagues also carried out another systematic 
review.4 investigating whether cannabis use affects the outcome 
of psychotic disorders as it is unclear if research findings support 
clinical opinion that cannabis use leads to worse outcomes in 
people with psychosis, or whether this impression is confounded 
by other factors. 
They observed that cannabis use was consistently associated 
with increased relapse and non- adherence. However it was 
noted that few studies adjusted for baseline illness severity, 
and most made no adjustment for alcohol, or other potentially 
important confounders. When these confounders were taken 
into consideration, the results became less convincing. Therefore 
it was difficult to be confident that most of the associations 
reported were specifically due to cannabis. Despite clinical 
opinion, it remains important to carry out further research 
to establish whether cannabis is harmful, what outcomes are 
particularly affected by cannabis use, and how these effects 
occur. Furthermore, unlike determining whether or not cannabis 
use increases risk of rare disorders such as schizophrenia, 
studies that examine questions about the effects of cannabis on 
the outcome of people with psychosis are very feasible.
Can cannabis use be reduced 
by psycho-education in psychotic patients?
Mark Agius, a Maltese doctor working in Luton, studied 
this issue in reporting on the outcomes of a service working 
for three years with patients who had suffered a first episode 
of psychosis. A group of patients in the early intervention (EI) 
service were compared to a group of patients who received 
‘treatment as usual in Community Mental health teams. More 
patients admitted to using illicit drugs at the beginning of the 
intervention in the EI group than in the CMHT group. Less 
patients in the EI group than in the CMHT group were using 
illicit drugs at the end of three years, indicating more patients 
stopped using illicit drugs in the EI group than in the CMHT 
group. This may be because of more effective psycho-education 
evident. Fourth, the authors also undertook separate analyses 
of individuals who only reported using cannabis at the initial 
assessment to try and tease out the effects of cannabis from those 
of other drugs. Zammit et al.3 found that cannabis use at baseline 
predicted an increased risk of schizophrenia during the follow-
up period in a dose–response manner. They demonstrated that 
the relation between cannabis use and schizophrenia persisted 
when they controlled for the effects of other drug use and other 
potential confounding factors, and that the association was very 
unlikely to have been due to self-medication. They estimated 
that, if the association was indeed causal, then about 13% of 
schizophrenia cases could be averted if all cannabis use was 
prevented. 
Subsequently Zammit and others conducted a systematic 
review of cannabis use and risk of psychotic or affective mental 
health outcomes.9 This was carried out to clarify whether 
cannabis can cause psychotic or affective symptoms that persist 
beyond transient intoxication. They systematically reviewed the 
evidence pertaining to cannabis use and occurrence of psychotic 
or affective mental health outcomes. Studies were included 
if longitudinal and population based. 35 studies from 4804 
references were included. There was an increased risk of any 
psychotic outcome in individuals who had ever used cannabis 
(pooled adjusted odds ratio=1·41, 95% CI 1·20–1·65). Findings 
were consistent with a dose-response effect, with greater risk in 
people who used cannabis most frequently (2·09, 1·54–2·84). 
Results of analyses restricted to studies of more clinically 
relevant psychotic disorders were similar. Depression, suicidal 
thoughts, and anxiety outcomes were examined separately.
Findings for these outcomes were less consistent, and fewer 
attempts were made to address non-causal explanations than 
for psychosis, and the authors were less confident about a causal 
relationship between cannabis use and these outcomes than they 
were for psychosis. A substantial confounding effect was present 
for both psychotic and affective outcomes, but the authors 
nevertheless concluded that the evidence that cannabis use 
increased the risk of psychotic illnesses such as schizophrenia 
was strong enough that individuals using cannabis should be 
advised about this risk.
How does cannabis use impact on psychosis?
Anton Grech, a Maltese Doctor working in both Malta 
and the Institute of Psychiatry, London, and others carried 
out a comparison between psychotic patients from two 
different cultural settings, South London and Malta.5 Cannabis 
consumption and use of other substances was much more 
widespread in the former. In both centres, psychotic patients 
abused substances much more than controls. A particularly 
strong association between cannabis abuse and psychosis 
was shown by the fact that the odds ratio for cannabis abuse 
in patients over controls was greater in both centres than the 
odds ratio for substance abuse in general or for any other type 
of substance. This showed a fairly constant association between 
cannabis and psychosis.
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in the EI group.10-11 Clearly, given what has been shown by Grech 
and by Zammit,4,6-8 that is, that cannabis makes psychotic 
illnesses worse, then interventions to reduce cannabis in this 
group are very important. The psych-education provided within 
the EI group is a relatively simple and cheap intervention, but 
could make a substantial difference to morbidity at a population 
level.
Conclusion
Maltese doctors have made a significant contribution to 
the development of knowledge about the relationship between 
cannabis and psychosis. While they have mostly worked in the 
UK, at least on one occasion, they have carried out research 
in Malta itself. Our aim in this article has been to chronicle 
the contribution of Maltese medical scientists to this area of 
research.
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